NCT07164469 2026-03-11
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT03696784 2025-12-08
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03016377 2025-10-27
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT01494103 2025-07-11
DOTTI
Baylor College of Medicine
Phase 1 Active not recruiting
NCT03056339 2024-03-25
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03594162 2021-12-03
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated